Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 7;10(11):e004974. doi: 10.1136/jitc-2022-004974

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

DNMTi treatment enhances secretion of pro-inflammatory chemokines from murine OC cells and increases migration of T cells. (A) ID8 Trp53^-/- Adar1 knockdown (shAdar1) and control cells (shGFP) were plated on day 0 and treated with DNMTi for three consecutive days without media change. Cell culture supernatant was collected on day 4 for chemokine/cytokine analysis with the BioLegend LEGENDplex Mouse Anti-Virus Response Panel. Chemokine/Cytokine levels were normalized by number of live cells. (C) Graphs show ratio of migrated CD4+ or CD8+ T cells to tumor cells. (D) Graphs show migration index, which is the fold change of DNMTi-treated migrated T cells to mock-treated migrated T cells (red and purple bars), or alternatively, the fold change of migrated T cells in the +CCL5 condition to the −CCL5 condition (gray bars). A one-way analysis of variance was performed for statistical significance. *P<0.05; **p<0.01; ***p<0.001. 5-AZA, 5-zaacytidine; DMSO, dimethyl sulfoxide; DNMTi, DNA methyltransferase inhibitor; IFN, interferon; OC, ovarian cancer.